We are humans revolutionizing the future of healthcare diagnostics through artificial intelligence

“Our peripheral neuropathy screening solution will revolutionize preventative care for diabetic patients.”

Peter Soliz (PhD)

About our company

VisionQuest Biomedical began with an idea — to simplify diagnosis of diabetic retinopathy in ever-increasing numbers of diabetes patients and bring cutting-edge artificial intelligence technology to everyday eye care.

That idea has evolved into a series of software products that empower hospitals, health-care centers, and laboratories to detect not only diabetic retinopathy, but also diabetic peripheral neuropathy (diabetic foot), cerebral malaria, and retinopathy of prematurity in the early stages of disease.

We have deployed our products and technology in seven countries and have served more than 50,000 patients. With the COVID-19 pandemic impacting many industries, quick, accessible, and contactless testing solutions are here to stay.

VisionQuest Biomedical was founded in 2007 with the goal of developing and commercializing advanced technologies aimed at improving care in diabetes.

Through grant funding from the National Institutes of Health and private investment this stated strategic objective is being met, as evidenced in the commercialization of two NIH-funded technologies at clinics screening for diabetic retinopathy.

VisionQuest has developed and successfully deployed a software product for automatic analysis of retinal images in the detection of lesions in patients with diabetic retinopathy, age-related macular degeneration (AMD), and glaucoma.

Our automatic, real-time image quality screening system is also now being used in two commercial retinal cameras to ensure the highest possible retinal image quality, critically important for reading centers to make the best possible determination of a case.

Timeline VisionQuest

VisionQuest Biomedical Milestones

2016

EyeStar deployed in Mexico

2017

Diabetic Foot testing device development.

2018

Aspire clinical testing in Africa

2020

+25,000 patients tested with Eyestar

2021

Bring Eyestar to USA

2022-2025

VisionQuest's products saving visions and lives Worldwide

Our mission is to develop and deploy image-based technologies to improve access to health care for millions of individuals in the United States and around the world, especially in the fields of diabetes and eye care.

Leadership


CTO & Founder

Peter SolizPhD

LinkedIn

Pete is the principal investigator on the NIH grants that funded the development of EyeStar. He continues his mission of developing AI technologies for health care and securing additional non-dilutive funding.

Our Team

Vinayak Joshi PhD

Senior Research Scientist

Vinayak obtained his PhD in biomedical engineering from the University of Iowa. He is the principal investigator for the Aspire AI software.

Jeff Wigdahl PhD

Research Scientist

Jeff specializes in developing software for retinal image analysis. He has developed software for the detection of retinopathy of prematurity, diabetic retinopathy, and hypertensive retinopathy.

He obtained his master’s degree from the University of New Mexico and his PhD from the University of Padova.

Dean Hoy

Controller

Dean has over 25 years of accounting experience in various industries including health-care R&D, oil and gas, and mining. He has extensive experience in financial reporting and budgeting.

He obtained his bachelor's of business administration from the University of Texas at Arlington.

Sheraz Saint-Lot

Administrative Assistant

Sheraz has over 35 years of administrative experience. She handles the duties of clinical coordinator for the i-RxTherm project and provides administrative assistance to VisionQuest’s leadership.

Our Partners

Contact Us

Send us a message, we want to hear from you.





This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.